Anti-GP2 IgA ELISA Kit

$350.00

The Anti-GP2 IgA ELISA Assay kit is used for the quantitative determination of IgA antibodies against glycoprotein 2 (GP2) in human serum for the diagnosis of Crohn’s disease. The Eagle Biosciences Anti-GP2 IgA is for research use only and not for use in diagnostic procedures.

SKU: G2A31-K01 Categories: , ,

Anti-GP2 IgA ELISA Kit

Anti-GP2 IgA ELISA Kit Developed and Manufactured by Medipan

Size: 1×96 wells
Sensitivity: 1 U/ml
Dynamic Range: 1 – 300 U/ml
Incubation Time: 1.5 hours
Sample Type: Serum, Plasma
Sample Size: 10 µL
Alternative Names: Anti-glycoprotein 2 IgA ELISA, GP2 IgA Antibody ELISA
For Research Use Only

Controls Included


Reference Values
Negative: < 5 U/ml Positive: > 10 U/ml
Grey Zone: 5-10 U/ml

Specimens with concentrations detected in the grey zone should be retested.
It is recommended that each laboratory establishes its own normal and pathological reference ranges for serum anti-glycoprotein 2 IgA levels, as usually done for other diagnostic parameters, too. Therefore, the above mentioned reference values only provide a guide to values which might be expected.


Assay Principle

The Anti-GP2 IgA ELISA Kit is an enzyme immunoassay for the quantitative determination of IgA antibodies to glycoprotein 2.

The antibodies of the calibrators, positive control, and diluted patient samples react with the antigen immobilized on the solid phase of microtiter plates. After an incubation period of 60 min at room temperature (18…25°C), unbound serum components are removed by a wash step.

The bound IgA autoantibodies react specifically with anti-human-IgA-antibodies conjugated to horseradish peroxidase (HRP) within the incubation period of 30 minutes at room temperature. Excessive conjugate is separated from the solid-phase immune complexes by the following wash step.

HRP converts the colorless substrate solution of 3,3’,5,5’-tetramethyl¬benzidine (TMB) added into a blue product. This enzyme reaction is stopped by dispensing an acidic solution (H2SO4) into the wells after 15 min at room temperature turning the solution from blue to yellow.

The optical density (OD) of the solution at 450 nm is directly proportional to the amount of specific antibodies bound. The standard curve is established by plotting the concentrations of the antibodies of the calibrators (x-axis) and their corresponding OD values (y-axis) measured. The concentration of antibodies of the specimen is directly read off the standard curve.


Related Products

Anti-GP2 (Glycoprotein 2) IgG ELISA Assay Kit
Anti-Beta2-Glycoprotein 1 IgM ELISA Assay Kit
Anti-Beta2-Glycoprotein 1 IgG ELISA Assay Kit

Additional Information

Assay Background


Non-specific inflammatory bowel disease including Crohn’s disease (Enteritis regionalis) and ulcerative colitis (UC) are characterised by unknown etiology as well as chronic-remitting inflammatory processes of the intestine. Whereas the inflammation of ulcerative colitis is restricted to the mucosa and submucosa of colon and rectum, Crohn’s disease (CD) shows a wide spread inflammation of gastro-intestinal tract with granuloma formation. The risk developing one of these diseases is strongly correlated to immunologic, genetic, infectious and environmental factors.

The differential diagnosis of inflammatory bowel diseases to chronic diarrhea, recurrent abdominal dolor, infectious colitis, anorexia as well as the differentiation of CD to UC is still a challenge.

Autoantibodies of exocrine pancreas (PAB) were identified as specific serological marker for CD. A prevalence of 39 % of these autoantibodies in patients with CD could be demonstrated by indirect immune fluorescence (Stöcker et al. 1987). Glycoprotein 2 (GP2), a membrane-bound pancreatic protein, could be identified/verified as the major target of PAB’s (Roggenbuck et al., 2009). In combination with the detection of autoantibodies to Saccharomyces cerevisiae (ASCA) with a prevalence of 70 % in patients with CD and atypical antineutrophile cytoplasmatic antigens (aANCA) which are mainly found in patients with UC, PAB’s against GP2 could be used as a highly specific serological marker for differential diagnosis of CD to UC.

Typical Standard Curve


Manual

Product Manual


Publications

Literature


  • Stöcker W, Otte M, Ulrich S, Normann D, Finkbeiner H, Stöcker K, Jantschek G, Scriba PC: Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl. 1987; 139: 41-52.
  • Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut, 2009;58:1620-8.